Dataset Information


Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study.

ABSTRACT: Bosutinib is approved for newly diagnosed Philadelphia chromosome-positive (Ph+) chronic phase (CP) chronic myeloid leukemia (CML) and for Ph+ CP, accelerated (AP), or blast (BP) phase CML after prior treatment with tyrosine kinase inhibitors (TKIs). In the ongoing phase 4 BYOND study (NCT02228382), 163 CML patients resistant/intolerant to prior TKIs (n?=?156 Ph+ CP CML, n?=?4 Ph+ AP CML, n?=?3 Ph-negative/BCR-ABL1+?CML) received bosutinib 500?mg once daily (starting dose). As of ?1 year after last enrolled patient (median treatment duration 23.7 months), 56.4% of Ph+ CP CML patients remained on bosutinib. Primary endpoint of cumulative confirmed major cytogenetic response (MCyR) rate by 1 year was 75.8% in Ph+ CP CML patients after one or two prior TKIs and 62.2% after three prior TKIs. Cumulative complete cytogenetic response (CCyR) and major molecular response (MMR) rates by 1 year were 80.6% and 70.5%, respectively, in Ph+ CP CML patients overall. No patient progressed to AP/BP on treatment. Across all patients, the most common treatment-emergent adverse events were diarrhea (87.7%), nausea (39.9%), and vomiting (32.5%). The majority of patients had confirmed MCyR by 1 year and MMR by 1 year, further supporting bosutinib use for Ph+ CP CML patients resistant/intolerant to prior TKIs.

SUBMITTER: Hochhaus A 

PROVIDER: S-EPMC7387243 | BioStudies | 2020-01-01

REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC5303616 | BioStudies
1000-01-01 | S-EPMC4737299 | BioStudies
2015-01-01 | S-EPMC5132035 | BioStudies
2014-01-01 | S-EPMC4467890 | BioStudies
2015-01-01 | S-EPMC5650096 | BioStudies
2018-01-01 | S-EPMC6071555 | BioStudies
2018-01-01 | S-EPMC5888919 | BioStudies
2020-01-01 | S-EPMC7322957 | BioStudies
2020-01-01 | S-EPMC7237399 | BioStudies
2012-01-01 | S-EPMC4916559 | BioStudies